4099642A-F8D6-428C-AA12-1E76C27BB368
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 57.55584756898817
- age_years
- 36
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- NOTCH_SIGNALING+0.504
- TGF_BETA_SIGNALING+0.471
- PROTEIN_SECRETION+0.454
- MITOTIC_SPINDLE+0.380
- MYC_TARGETS_V1+0.373
- WNT_BETA_CATENIN_SIGNALING+0.358
- INTERFERON_ALPHA_RESPONSE+0.324
- UV_RESPONSE_DN+0.285
- DNA_REPAIR+0.282
- G2M_CHECKPOINT+0.274
Top 10 suppressed
- KRAS_SIGNALING_DN-0.397
- PANCREAS_BETA_CELLS-0.349
- APICAL_SURFACE-0.243
- MYOGENESIS-0.234
- SPERMATOGENESIS-0.164
- COAGULATION-0.127
- UV_RESPONSE_UP-0.087
- APICAL_JUNCTION-0.071
- ESTROGEN_RESPONSE_LATE-0.055
- ANGIOGENESIS-0.053
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 53BA607F-7939-40D9-BEFA-DC4ABDC7630B | — | — | 0.938 |
| 2 | 745233F1-DF41-4DDA-9146-1666DD59355E | — | — | 0.919 |
| 3 | 0F8BE394-BA6A-401C-87D0-9B3CF50FB0C8 | — | — | 0.901 |
| 4 | 0A7A28BA-9D46-4D4F-A0A5-B3F9AA8DF29B | — | — | 0.900 |
| 5 | 7604968C-689A-458D-96BA-33B163B238F8 | — | — | 0.898 |
| 6 | 8BA4F4D7-5FCD-42B8-B000-108067FE6885 | — | — | 0.897 |
| 7 | SRR934764 | — | — | 0.895 |
| 8 | 0CEC1ADC-1E8E-4CAC-8DFD-E1A760064E58 | — | — | 0.893 |
| 9 | BE6A3670-34C4-4FD3-9794-C5B3254D9224 | — | — | 0.891 |
| 10 | 8EFB3C39-094A-4F91-8B8D-EE8A32AC7E1F | — | — | 0.886 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| NOTCH_SIGNALING | 0.504 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.471 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.454 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.380 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.373 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.358 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.324 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.285 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.282 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.274 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.270 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.254 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.252 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.244 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.225 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.215 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.209 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.208 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.203 | Inavolisib | — uncovered |
| PEROXISOME | 0.182 | Idelalisib | — uncovered |